Why is $KLRA moving today? · SEC 8-K archive

$KLRA SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $KLRA: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $KLRA filing catalyst

Why did $KLRA trigger an AI stock catalyst alert?

$KLRA triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: -2.5/10). Headline: Kailera Reports Q3 Net Loss Widening to $95.7M on Clinical Expansion. Key points: - Q3 net loss widened to $95.7M from $39.6M year-over-year as R&D spending surged. - Cash and cash equivalents stood at $106.5M vs $160.3M at prior period end. - Phase 3 oral Ribupatide initiation pushed to 1H 2027; Phase 2 readout expected mid-2027.

How did $KLRA stock react after the SEC filing?

After the SEC 8-K for $KLRA, observed market reaction: T0 price $12.80. Past moves do not guarantee future results.

Where can I get real-time $KLRA SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $KLRA via Telegram and the VIP Web Terminal from €10/month.

$KLRA

$KLRA – Kailera Reports Q3 Net Loss Widening to $95.7M on Clinical Expansion

Kailera Therapeutics, Inc.

2026-11-04 00:00:00 UTC · SEC 8-K · All $KLRA

Unlocked archive · Analyzed in <2s at T0

Bearish AI Sentiment (-2.5 / 10)

Q3 net loss widened to $95.7M from $39.6M year-over-year as R&D spending surged.
Cash and cash equivalents stood at $106.5M vs $160.3M at prior period end.
Phase 3 oral Ribupatide initiation pushed to 1H 2027; Phase 2 readout expected mid-2027.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →